Impact of NSAIDs prior authorization policy on patients' QoL

BACKGROUND: In 1996, the West Virginia Medicaid program targeted nonsteroidal antiinflammatory drugs (NSAIDs) for prior authorization (PA) to ensure cost-effective and appropriate utilization. PA guidelines required that patients must have tried and failed treatment with 2 different classes of gener...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2002-11, Vol.36 (11), p.1686-1691
Main Authors: Momani, AA, Madhavan, SS, Nau, DP
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Arthritis - drug therapy
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Comorbidity
Educational Status
Female
Health Policy
Humans
Male
Medicaid - organization & administration
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Quality of Life
Surveys and Questionnaires
Therapeutic Equivalency
Treatment Failure
West Virginia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: In 1996, the West Virginia Medicaid program targeted nonsteroidal antiinflammatory drugs (NSAIDs) for prior authorization (PA) to ensure cost-effective and appropriate utilization. PA guidelines required that patients must have tried and failed treatment with 2 different classes of generic NSAIDs before a brand-name NSAID could be approved. OBJECTIVE: To evaluate the impact of the requirement of PA for branded NSAIDs on the health-related quality of life (HRQoL) of patients who are chronic users of NSAIDs. DESIGN: Pre- and postintervention quasiexperimental design was used for this study. The sample consisted of continuously eligible Medicaid recipients who were
ISSN:1060-0280
1542-6270
DOI:10.1345/aph.1C008